Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 39 (3) , 296-306
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Fibrate treatment for primary biliary cirrhosisCurrent Opinion in Gastroenterology, 2014
- Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretionHepatology, 2013
- Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acidHepatology, 2012
- Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcomeJournal of Hepatology, 2011
- Treatment of Primary Biliary Cirrhosis with Ursodeoxycholic Acid, Budesonide and FibratesDigestive Diseases, 2011
- Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate–activated protein kinase–dependent induction of orphan nuclear receptor small heterodimer partner #Hepatology, 2009
- Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2006
- Estimating the mean and variance from the median, range, and the size of a sampleBMC Medical Research Methodology, 2005
- Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell ActivationJournal of Biological Chemistry, 2000
- Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α ActivatorsJournal of Biological Chemistry, 2000